The Netherlands is a major international trade and commerce gateway with a highly developed import and customs landscape. The country has a modern and efficient customs administration and is home to one of the busiest ports in the world, the Port of Rotterdam.
The region also has a long history of conducting clinical research and is known for its high-quality healthcare infrastructure and research expertise.
Some key factors contributing to this include; a supportive regulatory environment, robust infrastructure, experienced workforce, and access to patient populations contribute to its global appeal for clinical trials. Consequently, the Netherlands has a well-developed and favorable clinical trial landscape.
Supportive regulatory environment: The Dutch regulatory agency, the Medicines Evaluation Board (MEB), is known for its collaborative approach to drug development and innovation. The MEB is committed to facilitating the development and approval of new drugs and provides streamlined processes for clinical trial applications. Additionally, the Central Committee on Research Involving Human Subjects (CCMO) oversees the ethical aspects of clinical trials.
To conduct a clinical trial in the Netherlands, sponsors must obtain approval from both the MEB and the CCMO. The approval process involves submitting a clinical trial application with detailed information on the trial design, study population, investigational medicinal product (IMP), and safety monitoring plan. The application must also include information on the qualifications and experience of the investigators and the ethical considerations of the trial.
In addition to the approval process, there are several other regulatory requirements for clinical trials in the Netherlands. These include:
Robust infrastructure: The country has a strong healthcare infrastructure, with well-established academic medical centers, hospitals, and research institutions . Examples of such institutions include:
The country also has a high level of health literacy, which also helps to support patient recruitment and retention in clinical trials.
Experienced workforce: The region has a highly skilled and experienced workforce in clinical research, with many professionals trained in clinical trial design, management, and analysis. Additionally, many professionals in the Netherlands are fluent in English, making it easier for international sponsors to conduct trials there.
Access to patient populations: The state has a relatively small but distinctive population, including significant elderly and pediatric patients. This makes it an attractive location for clinical trials across various therapeutic areas.
A supportive regulatory environment, robust infrastructure, an experienced workforce, access to patient populations, and favorable reimbursement policies characterize the clinical trial landscape.
These factors make the Netherlands an attractive location for clinical trials and have helped to establish the country as a leading destination for drug development and innovation.
While the Dutch import and customs landscape is generally favorable, some distinct challenges are still associated with importing goods into the country. Some of the key challenges include:
Customs clearance: The Netherlands has strict customs regulations, which can lead to delays and additional costs associated with customs clearance and import duties. It is crucial to ensure that all necessary documentation is completed accurately and submitted promptly to avoid delays.
Some of the customs requirements in the Netherlands include the following:
Language barriers: While many professionals in the Netherlands are fluent in English, there may still be language barriers to overcome when importing goods, especially if dealing with customs officials or logistics providers who do not speak English.
While English language labeling for clinical trials may not necessarily be a roadblock. In the Netherlands, it is essential to consider regulatory requirements, informed consent, site staff, and investigator understanding in conjunction with local customs and preferences – particularly when determining the appropriate language for labeling in a clinical trial conducted in the region. It may be necessary to provide translations in Dutch or other relevant languages to ensure effective communication and compliance with local regulations and practices.
Cost: Importing goods can be expensive, especially when factoring in customs duties, transportation costs, and storage fees. Importers may need to carefully manage their budgets to ensure they can import the goods they need.
Compliance: Ensuring compliance with Dutch import regulations can be challenging, especially when dealing with controlled substances or other highly regulated materials. Compliance requirements can vary depending on the material being imported, so it is important to have a thorough understanding of the relevant regulations. Specific compliance features include:
For the Importer of Record (IOR) and Exporter of Record (EOR) requirements in the Netherlands, the local representative must be a company or individual registered for VAT. The IOR is responsible for providing all necessary documentation to Dutch customs authorities, paying applicable import duties or taxes, and ensuring proper storage and handling of trial materials while obtaining required permits or licenses. The EOR, on the other hand, is responsible for providing all necessary documentation to customs authorities in the destination country, complying with applicable export regulations, properly packaging and labeling trial materials, and obtaining any necessary permits or licenses.
It is important to note that the specific requirements for appointing an IOR and EOR may vary depending on the type of clinical trial, the trial materials being imported/exported, and other factors. You should consult with a local regulatory expert or legal advisor to ensure you comply with all applicable regulations.
Generally, goods imported into the Netherlands from outside the EU are subject to customs duties and VAT. However, certain exemptions and relief schemes are available for clinical trial materials. For example:
Based on these complexities, industry professionals and governing bodies have frequently expressed that importing medical devices into the Netherlands can be complex, requiring a thorough understanding of logistics and global supply chain processes and requirements. Furthermore, these agencies recommend collaboration with manufacturers, customs brokers, tax advisors, translation services, notified bodies, and insurance providers to ensure compliance and successful market entry of medical devices.
Ultimately it is important to work with experienced partners who understand the local regulations and can help to ensure compliance, streamline the import process, and take advantage of any available exemptions or relief schemes.
It is vital to work with experienced and knowledgeable partners, such as third-party service providers and a Qualified Person (QP), to ensure that all requirements are met and that the import process runs smoothly. And although the import process for clinical trials in the Netherlands can be challenging, proper preparation and attention to detail can help ensure the successful importation of IMPs for use in clinical trials.
TecEx Medical can project manage clinical trials from start to finish. Additionally, we offer VAT savings solutions and Import VAT recoverability.
This offers a more efficient and streamlined import and export process. Ultimately improving the operational function based on the specific needs of your trial.
We work proactively to bring you updated and engaging content regularly. Stay in the know with industry changes, information, and advice.
Transitioning from decentralized to centralized procurement in clinical trials is not merely a procedural shift; it's a strategic initiative. The…Read More »
Navigating the complex terrain of clinical trials, the shift from decentralized to centralized procurement emerges as a strategic odyssey. It…Read More »
Historically, there has never been a clear winner in the battle between centralized vs decentralized procurement for clinical trials. Yet,…Read More »
How can streamlined procurement reduce clinical trial overheads? Procurement costs can become a rugged terrain to navigate. Here, we identify…Read More »
In the world of clinical trials, the adoption of centralized procurement is gaining momentum as a strategic approach to not…Read More »
At the heart of a centralized procurement system lies the power to unify all purchasing operations, creating a composition of…Read More »